Sorrento Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.55 Insider Own6.35% Shs Outstand337.12M Perf Week21.77%
Market Cap533.89M Forward P/E0.18 EPS next Y8.42 Insider Trans-0.01% Shs Float276.34M Perf Month-18.38%
Income-471.70M PEG- EPS next Q-0.23 Inst Own24.60% Short Float19.78% Perf Quarter-50.49%
Sales57.00M P/S9.37 EPS this Y-11.90% Inst Trans0.86% Short Ratio5.68 Perf Half Y-75.57%
Book/sh0.67 P/B2.25 EPS next Y282.40% ROA- Target Price21.00 Perf Year-78.34%
Cash/sh0.77 P/C1.97 EPS next 5Y37.00% ROE- 52W Range1.15 - 11.07 Perf YTD-67.53%
Dividend- P/FCF- EPS past 5Y-3.70% ROI-169.30% 52W High-85.86% Beta2.45
Dividend %- Quick Ratio1.60 Sales past 5Y45.40% Gross Margin73.00% 52W Low36.09% ATR0.14
Employees799 Current Ratio1.60 Sales Q/Q28.70% Oper. Margin- RSI (14)45.78 Volatility10.34% 9.19%
OptionableYes Debt/Eq0.68 EPS Q/Q- Profit Margin- Rel Volume0.56 Prev Close1.51
ShortableYes LT Debt/Eq0.42 Earnings- Payout- Avg Volume9.62M Price1.57
Recom2.00 SMA201.29% SMA50-19.88% SMA200-68.49% Volume3,667,598 Change3.64%
Jan-29-21Initiated B. Riley Securities Buy $26
Jan-21-21Initiated Alliance Global Partners Buy $35
Jul-31-20Reiterated H.C. Wainwright Buy $24 → $30
May-26-20Initiated Dawson James Buy $24
Oct-07-19Initiated JMP Securities Mkt Outperform $21
Jun-28-18Initiated B. Riley FBR, Inc. Buy $14.25
Jan-16-18Reiterated H.C. Wainwright Buy $20 → $30
May-22-17Reiterated Rodman & Renshaw Buy $30 → $20
May-22-17Reiterated FBR & Co. Outperform $13 → $9
Oct-03-16Initiated ROTH Capital Buy
Apr-06-16Reiterated FBR Capital Outperform $21 → $16
Mar-16-16Reiterated FBR Capital Outperform $22 → $21
Dec-22-15Initiated FBR Capital Outperform $22
Dec-07-15Resumed Rodman & Renshaw Buy $45
Aug-03-15Resumed MLV & Co Buy $34
Jul-29-15Reiterated Brean Capital Buy $17 → $26
May-28-15Initiated Brean Capital Buy $17
Mar-17-15Reiterated H.C. Wainwright Buy $13 → $20
Oct-02-14Initiated H.C. Wainwright Buy $11
Jun-19-14Initiated MLV & Co Buy $9
May-18-22 09:30AM  
May-17-22 03:52PM  
May-16-22 05:15PM  
May-12-22 08:25AM  
May-11-22 09:00AM  
May-05-22 08:05PM  
May-03-22 09:15AM  
May-02-22 06:54PM  
Apr-28-22 09:00AM  
Apr-27-22 09:00AM  
Apr-25-22 12:46PM  
Apr-19-22 03:43PM  
Apr-12-22 09:15PM  
Apr-04-22 09:00AM  
Mar-31-22 05:55PM  
Mar-29-22 05:55PM  
Mar-27-22 08:00AM  
Mar-25-22 09:00AM  
Mar-24-22 08:55AM  
Mar-20-22 05:26PM  
Mar-18-22 05:30PM  
Mar-17-22 03:35PM  
Mar-15-22 07:15AM  
Mar-10-22 09:45AM  
Mar-02-22 11:37AM  
Feb-24-22 06:20PM  
Feb-22-22 09:00AM  
Feb-17-22 01:02PM  
Feb-11-22 03:00PM  
Feb-07-22 10:45AM  
Feb-02-22 03:38PM  
Feb-01-22 09:00AM  
Jan-28-22 09:00AM  
Jan-26-22 05:38PM  
Jan-24-22 09:00AM  
Jan-21-22 07:00AM  
Jan-20-22 05:38PM  
Jan-19-22 02:26PM  
Jan-18-22 09:00AM  
Jan-13-22 10:14AM  
Jan-10-22 01:35PM  
Jan-07-22 05:00PM  
Jan-06-22 05:38PM  
Jan-04-22 09:00AM  
Dec-31-21 05:56AM  
Dec-29-21 11:17AM  
Dec-28-21 04:48PM  
Dec-27-21 09:42AM  
Dec-21-21 04:22AM  
Dec-20-21 09:00AM  
Dec-13-21 11:33AM  
Dec-09-21 09:00AM  
Dec-07-21 01:42PM  
Dec-06-21 02:41PM  
Dec-05-21 02:28PM  
Nov-30-21 09:00AM  
Nov-29-21 09:00AM  
Nov-22-21 02:53PM  
Nov-16-21 05:17PM  
Nov-12-21 03:19PM  
Nov-11-21 08:00AM  
Nov-07-21 01:08PM  
Nov-03-21 10:06AM  
Nov-01-21 09:00AM  
Oct-29-21 03:00PM  
Oct-27-21 03:58PM  
Oct-26-21 06:11PM  
Oct-20-21 01:37PM  
Oct-13-21 09:30AM  
Oct-04-21 12:50AM  
Sep-28-21 02:23PM  
Sep-27-21 01:13PM  
Sep-19-21 02:58PM  
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. Additionally, the company has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patients with melanoma; and Karolinska Institutet. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Janda KimDirectorDec 27Option Exercise4.003,00012,0006,000Dec 27 07:34 PM
Janda KimDirectorDec 27Sale5.883,00017,6403,000Dec 27 07:34 PM
Ji HenrySee RemarksSep 29Option Exercise4.0010,00040,0002,055,807Sep 29 02:35 PM
Janda KimDirectorSep 27Option Exercise2.1142,35789,26445,357Sep 28 05:37 PM
Janda KimDirectorSep 27Sale8.0242,357339,7203,000Sep 28 05:37 PM
Janda KimDirectorSep 13Option Exercise3.508,00028,00011,000Sep 14 05:00 PM
Janda KimDirectorSep 13Sale8.048,00064,2853,000Sep 14 05:00 PM
Smith Robin LDirectorSep 03Option Exercise4.49175,000785,250235,000Sep 03 05:36 PM